Lentiviral Vector CDMOs — Ranked by Signal Score · 2026
50
CDMOs tracked
37
Fully scored
12
With FDA records
33
FDA inspections
92
EMA/MHRA GMP certs
On CDMO Signal's composite Signal Score, Thermo Fisher Scientific, AGC Biologics, and Lonza lead the lentiviral vector CDMO rankings. Signal Score is a 0–100 composite of four weighted pillars — Quality Compliance (35%), Operations (25%), Financial Stability (20%), and Capacity Intelligence (20%) — built from FDA inspection history, EMA/MHRA GMP certificates, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. Lentiviral vector CDMO selection typically comes down to BSL-2 containment integrity, suspension platform maturity, potency and RCL analytics, and a defensible regulatory record for material that lands in patient-bound cells. Rankings are recomputed daily. Full methodology at cdmosignal.com/methodology.
Lentiviral vectors are the workhorse of ex vivo gene therapy, used to engineer T cells for CAR-T and to modify hematopoietic stem cells. Because the vector ends up in patient-bound cells, manufacturers carry the regulatory weight of a critical starting material under full GMP.
Choosing a lentiviral vector CDMO comes down to BSL-2 containment, a mature suspension or adherent platform, robust analytics (titer, potency, RCL testing), and a clean regulatory record. The rankings below score each CDMO on FDA inspection history, GMP certification, clinical-program activity, and capacity signals.
FDA inspection outcomes across these CDMOs: 14 NAI (no action), 19 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: UNITED KINGDOM (35), United States (29), Denmark (18), Germany (8), France (7).
Last updated 2026-08-22. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
TF
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
|
83.1 | 97.9 | 6 insp · 10 GMP | Available | 2 programs |
| 2 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
80.6 | 99.9 | 2 insp · 23 GMP | Available | 2 programs |
| 3 |
Lonza
Basel, Switzerland
|
78.2 | 95.1 | 2 insp · 8 GMP | — | 1 programs |
| 4 |
OX
Oxford Biomedica
Oxford, United Kingdom
|
77.1 | 100.0 | 0 insp · 13 GMP | Available | 7 programs |
| 5 |
CI
Cincinnati Children's Vector Production Facility
Cincinnati, OH
|
75.2 | 100.0 | 1 insp · 0 GMP | — | 1 programs |
| 6 |
NR
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
|
73.4 | 97.7 | 1 insp · 0 GMP | Available | 9 programs |
| 7 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
91.7 | 98.7 | 8 insp · 11 GMP | Limited | 0 programs |
| 8 |
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
|
88.0 | 100.0 | 0 insp · 3 GMP | — | 0 programs |
| 9 |
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 3 insp · 0 GMP | Available | 0 programs |
| 10 |
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
|
81.0 | 98.8 | 4 insp · 8 GMP | — | 0 programs |
| 11 |
OB
OmniaBio
Hamilton, ON
|
79.5 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 12 |
SK
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | Available | 0 programs |
| 13 |
PG
ProBioGen
Berlin, DE
|
78.9 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 14 |
BB
bluebird bio Manufacturing
Durham, NC
|
78.5 | — | — | — | 0 programs |
| 15 |
AA
Ascend Advanced Therapies
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 16 |
NG
NecstGen
Leiden, NL
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 17 |
ET
Exothera
Jumet, BE
|
78.1 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 18 |
AD
Advent Bioservices
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 19 |
BV
Biovian
Turku, Finland
|
78.0 | 99.7 | 1 insp · 4 GMP | — | 0 programs |
| 20 |
AG2
August Bioservices
San Carlos, CA
|
77.4 | 98.5 | 1 insp · 0 GMP | — | 0 programs |
| 21 |
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
|
72.8 | 95.1 | 1 insp · 0 GMP | Limited | 0 programs |
| 22 |
VE
Vigene Biosciences
Rockville, MD
|
72.5 | — | — | — | 0 programs |
| 23 |
GZ
Genezen
Indianapolis, IN · Lexington, MA
|
70.7 | 84.1 | 3 insp · 0 GMP | Available | 0 programs |
| 24 |
IU
Indiana University Vector Production Facility
Indianapolis, IN
|
66.2 | — | — | — | 49 programs |
| 25 |
AN
Andelyn Biosciences
Columbus, OH
|
63.0 | — | — | Available | 0 programs |
| 26 |
RA
Recipharm Advanced Bio
Stockholm, Sweden (US operations: Watertown, MA; EU/global ATMP division of Recipharm AB)
|
63.0 | — | — | — | 0 programs |
| 27 |
GF
GeneFab
Alameda, CA and South San Francisco
|
61.5 | — | — | Available | 0 programs |
| 28 |
UB
uBriGene Biosciences
Shanghai, CN · Boston, MA
|
60.5 | — | — | — | 0 programs |
| 29 |
CoJourney Inc.
Horsham, PA (US HQ); Hangzhou, China (primary GMP manufacturing)
|
60.0 | — | — | Limited | 0 programs |
| 30 |
TR
Takara Bio
Kusatsu, Shiga Prefecture, Japan
|
59.5 | — | — | — | 8 programs |
| 31 |
MA
Matica Biotechnology
College Station, TX
|
59.0 | — | — | Available | 0 programs |
| 32 |
VB
VintaBio
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| 33 |
WB
Waisman Biomanufacturing
Madison, WI
|
59.0 | — | — | — | 0 programs |
| 34 |
EB
ElevateBio BaseCamp
Waltham, MA
|
59.0 | — | — | — | 0 programs |
| 35 |
VM
Vector BioMed
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| 36 |
AM
Anemocyte
Gerenzano, IT
|
59.0 | — | — | — | 0 programs |
| 37 |
DINAMIQS
Schlieren (Zurich), Switzerland
|
59.0 | — | — | Available | 0 programs |
| — |
3P Biopharmaceuticals (now 3PBIOVIAN)
Pamplona-Noáin, Spain
|
Profiled | — | — | — | 0 programs |
| — |
VIVEbiotech
San Sebastián, Spain
|
Profiled | — | — | — | 0 programs |
| — |
Rose BioSolutions
Wilmington, MA
|
Profiled | — | — | — | 0 programs |
| — |
Orphan Therapeutics Accelerator (OTXL)
Cambridge, MA
|
Profiled | — | — | — | 0 programs |
| — |
Porton Advanced
Cranbury, NJ
|
Profiled | — | — | — | 0 programs |
| — |
Vantage Vector (Demo)
Gaithersburg, MD
|
Profiled | — | — | Available | 0 programs |
| — |
Advanced BioScience Laboratories, Inc. (ABL Inc.)
Rockville, MD
|
Profiled | — | — | — | 0 programs |
| — |
Landmark Bio
Watertown, MA
|
Profiled | — | — | — | 0 programs |
| — |
IDT Biologika GmbH
Dessau-Roßlau, Germany
|
Profiled | — | — | — | 0 programs |
| — |
Pharmaron Biologics (Liverpool)
Liverpool, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Canton Biologics Co., Ltd.
Foshan (Shunde District), China
|
Profiled | — | — | — | 0 programs |
| — |
Canton Biologics
Guangzhou, China
|
Profiled | — | — | — | 0 programs |
| — |
Novasep
Lyon, France
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Lentiviral Vector CDMO
Containment & biosafety
Lentivirus requires BSL-2 manufacturing with segregated suites and validated decontamination. Confirm the site's containment design and replication-competent lentivirus (RCL) testing strategy.
Process platform maturity
Suspension culture scales more cleanly than adherent for larger batches. Ask whether the platform is serum-free and how it performs at your target dose and patient volume.
Analytics & potency
Titer, infectivity, and potency assays drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both are shown in the rankings above and on each profile.
Which lentiviral vector CDMOs handle commercial-scale supply?
Commercial-scale lentiviral vector supply is a narrow field. The commercial-scale lentiviral filter surfaces CDMOs with a top-quartile Signal Score, broad ClinicalTrials.gov sponsor footprint, or both. Leaders on that filter combine dense EMA/MHRA GMP certification with a track record of supplying vector to approved or late-stage cell therapies. Sponsors weighing commercial supply should verify not just capacity headroom but process comparability across sites — most late-stage lentiviral programs cannot afford tech transfer risk mid-development, and comparability data across a CDMO's global network is the diligence signal that matters.
How do BSL-2 lentiviral CDMOs differ on containment?
All GMP lentiviral manufacturing runs at BSL-2 with segregated suites, validated decontamination, and replication-competent lentivirus (RCL) testing — but CDMOs differ meaningfully in the maturity of their containment design. Suites may be single-product or multi-product, change-over cleaning varies in how rigorously it's validated, and site-level inspection history against lentivirus specifically is uneven. The FDA inspection record shown in the table above is the most objective signal here: CDMOs with clean lentiviral-specific 483 histories have demonstrated containment control under regulator scrutiny.
Which lentiviral CDMOs pair vector with cell therapy fill-finish?
Programs that need both lentivirus and downstream cell processing benefit from a CDMO — or CDMO group — that handles both in-house. Integration cuts tech transfer overhead, aligns release specs across drug substance and drug product, and removes a supply-chain seam. See the Cell Therapy CDMOs directory for the fuller cell therapy manufacturer view; CDMOs appearing in both lentiviral and cell therapy rankings are the integrated candidates worth prioritizing for combined-scope RFPs.
How CDMO Signal computes the lentiviral ranking
The lentiviral vector Signal Score is the platform's standard four-pillar composite. For lentiviral CDMOs specifically, the Quality pillar (35%) weights FDA inspection classifications (NAI, VAI, OAI) and EMA/MHRA GMP certificate density — both proxies for the containment-and-comparability track record that matters most in this modality. Operations (25%) reflects ClinicalTrials.gov sponsor breadth for programs matched to the CDMO. Financial Stability (20%) draws on SEC filings and parent-company health. Capacity Intelligence (20%) tracks monitored trade press for facility expansions and capacity additions. Full weightings, source lists, and edge cases at cdmosignal.com/methodology.
Lentiviral Vector CDMOs — Frequently Asked Questions
Who are the top Lentiviral Vector CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Lentiviral Vector CDMOs include Thermo Fisher Scientific, AGC Biologics, Lonza. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Lentiviral Vector CDMOs have FDA inspection records?
CDMO Signal tracks 12 Lentiviral Vector CDMOs with FDA inspection records and 92 EMA/MHRA GMP certificates across the group.
What should I look for in a lentiviral vector CDMO?
Prioritize BSL-2 containment, a mature suspension platform, qualified titer/potency/RCL assays, and a clean FDA and EMA/MHRA record. Match capacity to your dose and patient volume, and confirm tech-transfer support.
How is lentiviral vector manufacturing different from AAV?
Lentivirus integrates into the host genome and is produced under BSL-2 with RCL testing, typically for ex vivo cell engineering. AAV is non-integrating, made at higher volumes, and used mainly for in vivo gene therapy.
Related modalities